What is Anavex Life Sciences Operating Cash Flow per Share?
Anavex Life Sciences's operating cash flow per share for the
three
months ended in Mar. 2025 was $-0.07.
Anavex Life Sciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.35.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -5.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Anavex Life Sciences's Operating Cash Flow per Share or its related term are showing as below:
AVXL'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -329.1 Med: -6.95 Max: 51.5
Current: 5.3
During the past 13 years, Anavex Life Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.50% per year. The lowest was -329.10% per year. And the median was -6.95% per year.
AVXL's 3-Year OCF Growth Rate is ranked worse than 54.31% of 1217
companies
in the Biotechnology industry
Industry Median: 9.3
vs AVXL: 5.30
Anavex Life Sciences Operating Cash Flow per Share Historical Data
The historical data trend for Anavex Life Sciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Anavex Life Sciences Operating Cash Flow per Share Chart
Competitive Comparison of Anavex Life Sciences's Operating Cash Flow per Share
For the Biotechnology subindustry, Anavex Life Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 